SMCHD1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SMCHD1

NCBI ID: G23347

SMCHD1

SMCHD1: A Potential Drug Target and Biomarker for Various Diseases

SMCHD1 (Spermidine dehydratase 1) is a protein that is expressed in various cell types of the human body, including muscle cells, nerve cells, and cancer cells. It is a key enzyme in the DNA damage repair pathway, which is involved in the regulation of DNA replication and repair. SMCHD1 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, it has become an attractive target for drug development.

The DNA damage repair pathway is a critical network that helps maintain the integrity of DNA in the cell. This pathway involves a series of complex cellular processes that involve the activation of various enzymes and the formation of repair products. One of the key enzymes in this pathway is SMCHD1, which is a protein that is involved in the conversion of DNA strands that have become damaged or broken into single strands. This process is critical for the accurate and timely repair of DNA damage, and is therefore important for the development and survival of cells.

SMCHD1 is a member of the SMCHD family, which includes a variety of enzymes that are involved in the DNA damage repair pathway. These enzymes work together to ensure that damaged DNA is properly repaired and that the cell is able to continue to function properly. SMCHD1 is specifically involved in the repair of single-stranded DNA breaks, and is essential for the formation of the repair product that is required for the DNA double-strand to be fully repaired.

In addition to its role in the DNA damage repair pathway, SMCHD1 has also been shown to play a role in the development and progression of various diseases. For example, SMCHD1 has been shown to be involved in the development of cancer, particularly in the development of breast cancer. Studies have shown that high levels of SMCHD1 expression are associated with the development of breast cancer, and that inhibiting SMCHD1 activity may be an effective way to treat this disease.

Another promising aspect of SMCHD1 is its potential as a drug target. By inhibiting the activity of SMCHD1, it may be possible to treat a variety of diseases that are caused by the DNA damage repair pathway. This is because many diseases are caused by the misfunctioning of this pathway, and by inhibiting SMCHD1 activity, it may be possible to treat these diseases.

In addition to its potential as a drug target, SMCHD1 is also an attractive biomarker for the diagnosis and prognosis of various diseases. For example, high levels of SMCHD1 expression have been shown to be associated with the development of certain diseases, such as cancer. This suggests that SMCHD1 may be a useful biomarker for the diagnosis and prognosis of these diseases.

Overall, SMCHD1 is a protein that is involved in the DNA damage repair pathway and has been shown to play a role in the development and progression of various diseases. As a result, it is an attractive target for drug development and a useful biomarker for the diagnosis and prognosis of these diseases.

SMCHD1 is a protein that is expressed in various cell types of the human body, including muscle cells, nerve cells, and cancer cells. It is a key enzyme in the DNA damage repair pathway, which is involved in the regulation of DNA replication and repair . SMCHD1 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, it has become an attractive target for drug development and a useful biomarker for the diagnosis and prognosis of these diseases.

Protein Name: Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1

Functions: Non-canonical member of the structural maintenance of chromosomes (SMC) protein family that plays a key role in epigenetic silencing by regulating chromatin architecture (By similarity). Promotes heterochromatin formation in both autosomes and chromosome X, probably by mediating the merge of chromatin compartments (By similarity). Plays a key role in chromosome X inactivation in females by promoting the spreading of heterochromatin (PubMed:23542155). Recruited to inactivated chromosome X by Xist RNA and acts by mediating the merge of chromatin compartments: promotes random chromatin interactions that span the boundaries of existing structures, leading to create a compartment-less architecture typical of inactivated chromosome X (By similarity). Required to facilitate Xist RNA spreading (By similarity). Also required for silencing of a subset of clustered autosomal loci in somatic cells, such as the DUX4 locus (PubMed:23143600). Has ATPase activity; may participate in structural manipulation of chromatin in an ATP-dependent manner as part of its role in gene expression regulation (PubMed:29748383). Also plays a role in DNA repair: localizes to sites of DNA double-strand breaks in response to DNA damage to promote the repair of DNA double-strand breaks (PubMed:25294876, PubMed:24790221). Acts by promoting non-homologous end joining (NHEJ) and inhibiting homologous recombination (HR) repair (PubMed:25294876)

The "SMCHD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMCHD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets